Urinary levels of matrix metalloproteinases and their tissue inhibitors in nephrotic children

被引:19
作者
Wasilewska, Anna M. [1 ]
Zoch-Zwierz, Walentyna M. [1 ]
机构
[1] Med Univ Bialystok, Dept Pediat & Nephrol, PL-15274 Bialystok, Poland
关键词
children; cyclosporine A; MMP2; MMP9; nephrotic syndrome; TIMP1; TIMP2;
D O I
10.1007/s00467-008-0881-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
The aim of this study was to determine the effects of cyclosporine A (CyA) on urinary levels of matrix metalloproteinase 2 and 9 (MMP2, MMP9) and their tissue inhibitors 1 and 2 (TIMP1, TIMP2) in steroid-dependent nephrotic syndrome (SDNS). The study group (1) consisted of 18 children SDNS aged 3.5-17.0 years treated with CyA. All NS children were examined three times: (A) at proteinuria relapse, before CyA treatment, (B) after 6 months, and (C) after 12 months of CyA administration. The control group (2) consisted of 18 healthy children. Serum CyA level was assessed by immunofluorescence. Enzyme-linked immunosorbent assay kits for total human MMP2 and 9 and TIMP1 and 2 were obtained from R&D Systems. Compared with healthy controls, urinary MMP9/Cr in NS children before CyA was on the same level and increased during CyA treatment, and urinary TIMP1/Cr was twice as high and increased significantly during CyA treatment. MMP9/TIMP1 in NS children treated with CyA increased, but the difference was not statistically significant. Urinary MMP2/Cr was similar, and urinary TIMP2/Cr was significantly higher in children treated with CyA (p < 0.01). The MMP2/TIMP2 ratio in NS children treated with CyA was significantly lower in comparison with healthy controls (p < 0.01). A negative correlation was noted between urinary MMP2/TIMP2 ratio and serum CyA in NS children (r=-0.541, p < 0.01). An imbalance within the MMP2 and TIMP2 and MMP9 and TIMP1 system may play a role in the pathogenesis CyA nephropathy.
引用
收藏
页码:1795 / 1802
页数:8
相关论文
共 41 条
[1]  
ABRASS CK, 1995, WESTERN J MED, V162, P318
[2]  
Akiyama K, 1997, RES COMMUN MOL PATH, V95, P115
[3]   Chronic cyclosporine nephrotoxicity [J].
Andoh, TF ;
Bennett, WM .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 1998, 7 (03) :265-270
[4]  
ANTONOVYCH TT, 1998, TRANSPL P, V20, P951
[5]   Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart [J].
Bianchi, R ;
Rodella, L ;
Rezzani, R .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2003, 3 (03) :427-433
[6]   HUMAN GLOMERULI EXPRESS TIMP-1 MESSENGER-RNA AND TIMP-2 PROTEIN AND MESSENGER-RNA [J].
CAROME, MA ;
STRIKER, LJ ;
PETEN, EP ;
MOORE, J ;
YANG, CW ;
STETLERSTEVENSON, WG ;
STRIKER, GE .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (06) :F923-F929
[7]   MATRIX METALLOPROTEINASES AND CARDIOVASCULAR-DISEASE [J].
DOLLERY, CM ;
MCEWAN, JR ;
HENNEY, AM .
CIRCULATION RESEARCH, 1995, 77 (05) :863-868
[8]   Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporine nephropathy [J].
Duymelinck, C ;
Deng, JT ;
Dauwe, SEH ;
De Broe, ME ;
Verpooten, GA .
KIDNEY INTERNATIONAL, 1998, 54 (03) :804-818
[9]   RENAL EXPRESSION OF GENES THAT PROMOTE INTERSTITIAL INFLAMMATION AND FIBROSIS IN RATS WITH PROTEIN-OVERLOAD PROTEINURIA [J].
EDDY, AA ;
GIACHELLI, CM ;
MCCULLOCH, L ;
LIU, E .
KIDNEY INTERNATIONAL, 1995, 47 (06) :1546-1557
[10]   LONG VERSUS STANDARD PREDNISONE THERAPY FOR INITIAL TREATMENT OF IDIOPATHIC NEPHROTIC SYNDROME IN CHILDREN [J].
EHRICH, JHH ;
BRODEHL, J .
EUROPEAN JOURNAL OF PEDIATRICS, 1993, 152 (04) :357-361